The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prospective correlative study of FDG-PET SUV and proteomic profile (VeriStrat) of non-small cell lung cancer patients treated with erlotinib.
Chiara Lazzari
No relevant relationships to disclose
Marcello Tiseo
No relevant relationships to disclose
Vanesa Gregorc
No relevant relationships to disclose
Fiorenza Latteri
No relevant relationships to disclose
Massimo Ippolito
No relevant relationships to disclose
Segio Balderi
No relevant relationships to disclose
Sebastiano Cosentino
No relevant relationships to disclose
Maura Scarlattei
No relevant relationships to disclose
Heinrich Roder
Employment or Leadership Position - Biodesix
Stock Ownership - Biodesix
Julia Grigorieva
Employment or Leadership Position - Biodeesix
Stock Ownership - Biodesix
Joanna Roder
Employment or Leadership Position - Biodesix
Stock Ownership - Biodesix
Roberto Bordonaro
No relevant relationships to disclose
Andrea Ardizzoni
No relevant relationships to disclose
Luca Gianni
No relevant relationships to disclose
Hector J. Soto Parra
No relevant relationships to disclose